Webcast: A Paradigm Shift to Realize Intelligent Clinical Trial Oversight
On Demand Webinar
A Paradigm Shift to Realize Intelligent Clinical Trial Oversight
The usual approach of adding technology and headcount to manage today’s clinical trials is not sustainable or scalable. In this webinar, Nick Dyer (CEO, Catalyst Clinical Research) discusses the challenges his team has experienced with complex early phase oncology studies, and why they chose Medidata’s CTMS to help Catalyst attain operational success.
Stacey Yount (VP of Product – Trial Management Solutions, Medidata) will also discuss how Rave CTMS delivers expected efficiencies and more importantly, enables you to be effective.
You will learn how to:
- Cut through the data noise and make smarter decisions
- Break down the silos and improve collaboration
- “See” issues and remediate before they become big problems
This paradigm shift enabling Intelligent Oversight provides scalability and flexibility to meet and exceed expectations, now and in the future.
CEO, Catalyst Clinical Research
As a 21-year industry veteran, Nick joined Catalyst in October 2018 as CEO in leading service and geographic expansions. From 2011 to 2018, Nick was Chief Commercial Officer and later President of Novella Clinical. He has passionately embraced the need for therapeutically-focused CRO solutions interlaced with a flexible biopharma customer service model. Nick has also held various leadership positions with Quintiles (IQVIA) and PPD Development working in and/or leading a range of functions spanning Clinical Operations, Finance, IT, and Sales/Marketing.
Vice President of Product, Trial Management Solutions, Medidata
Stacey Yount has over 19 years in clinical research including experience in clinical data management, clinical operations, statistics, CROs, and central laboratories. Prior to joining Medidata in 2015, Stacey spent 5 years with Covance where she held several leadership positions including Vice President of Project Management, Data Management, and Alliance Management. Prior to joining Covance, Stacey spent 10 years with Eli Lilly.